Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide fMRI in Diabetes and Obesity
NCT01562678Phase 4Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Mar 2012
- Primary completion
- May 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing Liraglutide First with Placebo First (2 arms). Primary endpoint: Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization at 18 days. Started Mar 2012; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT01562678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562678.